Trevor A Sheldon, Andrew F Long, Nick Freemantle, Fujian Song The paper by Torgerson et al (p 48)1 is useful in that it describes a place where we would like to be, where there is perfect information on effectiveness, relevant outcome data, and reliable data on marginal costs. It also allows us the opportunity of clarifying the role of the Effective Health Care bulletins and of discussing some of the problems we have encountered over nearly three years of reviewing the literature.
The Effective Health Care bulletins were commissioned by the Department of Health at a time when it was realised that setting up the mechanisms of the internal market would not automatically result in the purchasing and provision of health care which was evidence based. The health service (and purchasers in particular) needed research based "intelligence" to inform their work. The aim of the bulletins was, "to provide valid and systematic data to aid purchasers in purchasing and providing health care ... to help decision makers in the health service make more informed decisions using the latest available information on the effectiveness of particular health interventions."2 The bulletins are based primarily on a systematic review and synthesis of published (and peer reviewed) literature on the clinical effectiveness of healthcare interventions. This is supplemented whenever possible with evidence on cost effectiveness, together with consideration of some issues surrounding the acceptability of the interventions being examined.3 They are intended to provide credible summaries of the evidence, but not guidelines, to inform choice, but not to determine decisions, and their use will reflect NHS priorities rather than set them. In this paper we address the broad issues raised by Torgerson et al.
of interest to clinicians, reviews of the literature will only rarely be able to examine these broader effects. We highlighted this problem in the bulletins several times. For example, "The management of infertility should be evaluated according to the degree to which it has been successful in reducing stress, distress, or social handicap.... This could involve, for example, measures of the extent to which treatment helps couples come to terms with their childlessness."4 However, nearly all of the evidence on the effectiveness of treatments concentrated on reproductive outcomes. In our review of the surgical treatment of glue ear we recommend that "research should use broader measures of outcome than just hearing loss"5 and in the bulletin on stroke services we argued for "the development and use of patient and carer centred outcomes such as measures of well being, quality of life, and satisfaction."6 Pointing to the lack of information on these types of outcomes for interventions is useful because it identifies uncertainties about the effectiveness of treatments bulletins, by systematically reviewing the evidence on clinical effectiveness, address this issue as first among equals. Such evidence is scattered through the literature, is of variable quality, and is often difficult to interpret. By reviewing the research literature and providing focused and accessible reviews targeted at key decision makers, there is a greater likelihood that the information used by decision makers will be reliable. Torgerson et al are right to draw attention to the need, when evaluating health care, to consider broader measures of outcome which are important to and valued by patients. However, because most research uses only those outcomes which are easy to measure or generated much debate.' 9 Despite the limitations in the literature, however, the information on clinical effectiveness can be useful. It enabled us to highlight, for example, that much gynaecological surgery was relatively ineffective for subfertility due to significantly blocked fallopian tubes and so reveal that these resources were being wasted4; that screening for osteoporosis was unlikely to have much impact on the number of hip fractures in elderly women2; that a proportion of operations for glue ear might be unnecessary5; that cholesterol screening was unlikely to have much effect on coronary heart disease'; that newer antidepressants were not substantially better to justify their routine first line use'; and that brief interventions can reduce alcohol consumption.1I1 Economic analysis The Effective Health Care bulletins concentrate primarily on clinical effectiveness rather than economics because effectiveness is a necessary condition for cost effectiveness. In some of the topics reviewed so far evidence for effectiveness was so lacking that the issues of cost effectiveness were irrelevant.
There is little information on costs in the NHS and few reliable economic analyses which we have been able to incorporate in our reviews. Where the evidence exists, the bulletins attempt to provide information on costs (sometimes in the form of a cost effectiveness analysis) so that decision makers can take into account the cost implications of various actions. For example, the bulletin on treatments for depression (one of three bulletins not mentioned by Torgerson et a!) gave detailed costing.'0 When reviewing bone density screening we estimated the cost of starting up a bone screening and treatment programme which could then be related to the potential benefits reported.2 The costs per cycle of each element of a subfertility service (for example, in vitro fertilisation, tubal surgery, clomiphene citrate treatment) and the corresponding increase in the pregnancy rate per cycle was estimated.4 From this a purchaser can explore the relative cost effectiveness of different options. We also included the possible extra costs due to demand for neonatal intensive care services resulting from assisted conception. The review could not, nor was intended to, advise purchasers as to the level of resources (if any) to devote to subfertility A services.
Cost-benefit analysis is widely acknowledged as the most powerful of the techniques of economic evaluation. However, its use poses several theoretical and practical problems and its application is rare in healthcare evaluation. ' irrelevance of drug treatment in the context of the self perceived underlying cause of the depression, or both. In the bulletin on managing depression, of necessity, we focused exclusively on compliance.'0 Indeed, this was particularly important since the new selective serotonin reuptake inhibitors (SSRIs) were being marketed largely on the basis of alleged improved acceptability to patients -which our meta-analysis did not confirm. '3 Given the lack of recorded information in clinical research on acceptability of treatment to patients -even side effects are poorly recorded in published papers -limited attention in the bulletins to issues of acceptability of treatment to patients and clinicians is unsurprising. From a clinical perspective compliance and uptake are critical; from a patient or user perspective the issue is Acceptability to patients undoubtedly has a great impact on the effectiveness of treatments ...
broader, including patients' attitudes and perceptions of the clinical condition, its prognosis, and side effects of treatment. Acceptability to patients undoubtedly has a great impact on the effectiveness of treatments but has been poorly addressed within biomedical research.8 9
Cost of illness Torgerson et al maintain that the choice of topics in the bulletins is critically based on a burden of illness criterion, but this is incorrect. The choice is based on three explicit criteria: the intervention has a high resource implication, its effectiveness is uncertain or disputed, and it probably has a large impact on health gain. 
